Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Waseem Barham

Interventional Cardiology South Bend, IN Medical Doctor

NPI 1053540203 CMS profile 2135

610 N Michigan St Ste 400, South Bend, IN 46601

Open in the dashboard

General payments

$13,479

229 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Waseem Barham of South Bend, IN is reported in the CMS Open Payments database as having received $13,479 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,191 32
2024 General $3,092 54
2023 General $5,951 58
2022 General $414 19
2021 General $355 23
2020 General $470 13
2019 General $1,006 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Waseem Barham
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Waseem Barham were reported at $2,191. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Waseem Barham Interventional Cardiology median Middle half National median
2019 $1,006 $1,097 $329–$3,048 $163
2020 $470 $473 $161–$1,480 $114
2021 $355 $677 $233–$1,827 $132
2022 $414 $978 $333–$2,724 $149
2023 $5,951 $1,136 $382–$2,986 $160
2024 $3,092 $1,181 $395–$3,326 $164
2025 $2,191 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $3,677 43 payments
  2. Boston Scientific Corporation $3,479 30 payments
  3. Abbott Laboratories $1,095 9 payments
  4. Abiomed $981 8 payments
  5. Novartis Pharmaceuticals Corporation $796 36 payments
  6. Philips Electronics North America Corporation $753 5 payments
  7. Shockwave Medical, Inc $524 12 payments
  8. Medtronic, Inc. $303 5 payments
  9. E.R. Squibb & Sons, L.L.C. $218 12 payments
  10. Janssen Pharmaceuticals, Inc $213 14 payments
  11. Other $1,442 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $6,893 32 payments
  2. Food and Beverage $6,447 194 payments
  3. Education $139 3 payments
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,754 33 payments
  2. TRICLIP $1,070 8 payments
  3. AngioJet Ultra 5000A $916 2 payments
  4. Impella $813 5 payments
  5. ENTRESTO $739 33 payments
  6. SAPIEN 3 Ultra RESILIA $428 8 payments
  7. (9520) IGT Devices Undivided $317 1 payment
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $311 10 payments
  9. SYMPLICITY G3 $236 4 payments
  10. XARELTO $213 14 payments
  11. Other $3,603 111 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

44

Median for Cardiology: 2,533

Drug cost

$544

Median for Cardiology: $485,213

Branded share of claims

36.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 16 $371
Metoprolol Succinate Generic 17 $88
Atorvastatin Calcium Generic 11 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $57
$57 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $54
$54 — —
ELIQUIS
  • PFIZER INC. $23
$23 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $19
$19 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record